Hyunchul Jung1,10, Hong Sook Kim2,10, Jeong Yeon Kim1, Jong-Mu Sun2, Jin Seok Ahn2, Myung-Ju Ahn2, Keunchil Park2, Manel Esteller3,4,5,6,7, Se-Hoon Lee2,8,* & Jung Kyoon Choi1,9,*
1 Department of Bio and Brain Engineering, KAIST, Daejeon 34141, Republic of Korea.
2 Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
3 Cancer Epigenetics and Biology Program (PEBC), Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet, Barcelona, Catalonia, Spain.
4 Centro de Investigacion Biomedica en Red Cancer (CIBERONC), 28029 Madrid, Spain.
5 Institucio Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Catalonia, Spain.
6 Physiological Sciences Department, School of Medicine and Health Sciences, University of Barcelona (UB), Barcelona, Catalonia, Spain.
7 Josep Carreras Leukaemia Research Institute (IJC), Badalona, Barcelona, Catalonia, Spain.
8 Department of Health Sciences and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul 06351, Republic of Korea.
9 Penta Medix Co., Ltd., Seongnam-si, Gyeongi-do 13449, Republic of Korea.
10 These authors contributed equally: Hyunchul Jung, Hong Sook Kim.
*Correspondence and requests for materials should be addressed to S.-H.L. or to J.K.C.